KMDA
Kamada Ltd.
Set alert
- YTD
- +9.07%
- 1 year
- +12.90%
- Open
- 7.88
- Prev close
- 7.95
- Mkt cap
- 444.37M
- Vol
- 47.51K
- Avg vol
- 126.00K
- EPS
- 0.38
- P/E
- 20.26
- Div yield
- 0.00%
More statistics
- Low
- 7.67
- High
- 7.88
- Forward P/E
- 19.52
- Beta
- 0.20
- Short ratio
- 0.94
- Inst. own
- 50.10%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.77
- 200-d avg
- 5.52
- 1y target
- 14.67
Key statistics
- Market cap
- 359.56M
- Enterprise value
- 276.22M
- Trailing P/E
- 22.41
- Forward P/E
- 19.52
- PEG ratio
- 0.00
- Price / sales
- 2.33
- Price / book
- 1.43
- EPS (TTM)
- 0.27
- Beta
- 0.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 9.75%
- Revenue (TTM)
- 154.57M
- Revenue growth
- 13.40%
- Free cash flow
- -7.77M
- Total cash
- 56.55M
- Total debt
- 8.56M
- Return on equity
- 7.04%
- Shares outstanding
- 57.49M
- Short % of float
- 0.09%
- 50-day average
- 5.77
- 200-day average
- 5.52
Analyst view
Consensus: none
- Target (low)
- 11.00
- Target (mean)
- 14.67
- Target (high)
- 20.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.06.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.07 | 0.07 | 0.00 | 0.00% |
| Aug 14, 2024 | Jun 1, 2024 | 0.06 | 0.08 | +0.02 | +33.33% |
| May 8, 2024 | Mar 1, 2024 | 0.06 | 0.04 | -0.02 | -33.33% |
| Mar 6, 2024 | Dec 1, 2023 | 0.05 | 0.09 | +0.04 | +80.00% |
| Nov 13, 2023 | Sep 1, 2023 | 0.03 | 0.06 | +0.03 | +100.00% |
| Aug 16, 2023 | Jun 1, 2023 | 0.02 | 0.04 | +0.02 | +100.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 3, 2024 | Stifel | init | — | Buy |
| May 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Kamada Ltd.
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Israel
- Website
- kamada.com
News
- Kamada Expands Biosimilar Portfolio With Commercial Launch Of Two Additional New Products In Israel, Adding To Existing Portfolio Of Two Products
- Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $202.048M Est
- Kamada Q2 EPS $0.16 Beats $0.12 Estimate, Sales $54.921M Beat $50.657M Estimate
- Kamada Signs $50M Plasma Supply Agreement With Biopharma Partner Through Texas Centers, Commercial Sales Starting Q4 2026
- Kamada Highlights Results Of An Investigator-initiated Study Of Cytogam, The Company’s Cytomegalovirus Immune Globulin, In The Management Of Cytomegalovirus In Solid Organ Transplantation
- Kamada Announces FDA Approval Of New In-House Rapid Fluorescent Focus Inhibition Test Laboratory
- Kamada Q1 2026 Earnings Call: Complete Transcript
- Earnings Scheduled For May 13, 2026
- Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $201.581M Est
- Kamada Q1 EPS $0.07 Misses $0.12 Estimate, Sales $45.240M Miss $46.722M Estimate
Your note
Sign in to keep a note on KMDA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Phoenix Holdings Ltd. | 3.19% | 1,832,952 | 11.09M | Sep 29, 2024 |
| Vanguard Group Inc | 2.41% | 1,384,430 | 8.38M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.49% | 856,106 | 5.18M | Sep 29, 2024 |
| Y.D. More Investments Ltd | 1.23% | 709,551 | 4.29M | Sep 29, 2024 |
| Wells Fargo & Company | 1.10% | 629,884 | 3.81M | Sep 29, 2024 |
| Millennium Management Llc | 0.62% | 354,776 | 2.15M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard International Stock Index-Total Intl Stock Indx | 1.13% | 650,238 | 3.93M | Jul 30, 2024 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 0.54% | 308,828 | 1.87M | Sep 29, 2024 |
| DFA Continental Small Company Series | 0.35% | 203,071 | 1.23M | Jul 30, 2024 |
| Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 0.26% | 146,585 | 886.84K | Jul 30, 2024 |
| DFA International Core Equity Portfolio | 0.14% | 78,512 | 475.00K | Jul 30, 2024 |
| Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 0.13% | 73,700 | 445.88K | Aug 30, 2024 |